Cellular & Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Physiology & Pharmacology Department, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
J Cell Physiol. 2018 Jan;234(1):23-32. doi: 10.1002/jcp.26865. Epub 2018 Aug 4.
Although, current medications for Parkinson's disease can control and relief symptoms of the disease efficiently, they are unable to either prevent progression of the disease or maintain their controlling ability as a long-term medication. To find suitable adjuvant and/or alternative treatments, researchers have investigated antioxidative and anti-inflammatory approaches, since emerging evidence consider oxidative stress and neuroinflammation as leading causes of the development of Parkinson's disease. Here, how oxidative stress and neuroinflammation take part in Parkinson's disease pathogenesis was discussed based on featured studies in this context. Then, preclinical and clinical trial studies, which evaluated antioxidative and anti-inflammatory compounds' ability to treat Parkinson's disease, were reviewed.
虽然目前用于帕金森病的药物能够有效地控制和缓解疾病症状，但它们既不能预防疾病的进展，也不能作为长期药物维持其控制能力。为了寻找合适的辅助治疗方法和/或替代疗法，研究人员已经研究了抗氧化和抗炎方法，因为越来越多的证据表明氧化应激和神经炎症是帕金森病发展的主要原因。在这里，根据这方面的特色研究，讨论了氧化应激和神经炎症如何参与帕金森病的发病机制。然后，综述了评估抗氧化和抗炎化合物治疗帕金森病能力的临床前和临床试验研究。
